Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.
Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org
Medicine name : Tecvayli
Generic name : Teclistamab
Manufactured By : Johnson & Johnson (Janssen)
Indications : Monotherapy for adults with relapsed or refractory multiple myeloma following at least one prior line of therapy.
Medicine Description : A bispecific antibody therapy for adults with relapsed or refractory multiple myeloma. Tecvayli (Teclistamab) binds to BCMA on myeloma cells and CD3 on T cells, helping the immune system recognise and destroy cancer cells.
Tecvayli (Teclistamab) is a prescription immunotherapy medicine used to treat adults with relapsed or refractory multiple myeloma. It is a bispecific antibody that helps the immune system recognise and destroy cancer cells.
Tecvayli binds to BCMA on multiple myeloma cells and CD3 on T cells. This brings the two cells together and activates T cells to attack and destroy cancer cells.
Tecvayli is prescribed for eligible adults with relapsed or refractory multiple myeloma. Treatment eligibility depends on the approved indication in the country and the patient’s previous treatments and medical condition.
Tecvayli is administered as a subcutaneous injection by a qualified healthcare professional. Treatment starts with step-up doses followed by a maintenance schedule prescribed by the oncologist.
Common side effects include fever, cytokine release syndrome, muscle and bone pain, injection site reactions, fatigue, upper respiratory tract infections, nausea, headache, pneumonia and diarrhoea.
Yes. Serious side effects may include severe cytokine release syndrome, neurological toxicity such as ICANS, serious infections, low blood cell counts and liver problems. Seek immediate medical attention for severe or unusual symptoms.
Treatment duration depends on the patient’s response, tolerability and the oncologist’s treatment plan. Tecvayli is generally continued until disease progression or unacceptable toxicity, according to the prescribed regimen.
Alcohol consumption should be discussed with your oncologist. Avoid or limit alcohol, particularly if you experience dizziness, fatigue or other treatment-related complications.
Tecvayli may cause harm to an unborn baby. Women of reproductive potential should use effective contraception during treatment and for 5 months after the last dose.
Yes. Always inform your doctor about all prescription medicines, over-the-counter products, vitamins and herbal supplements. Your healthcare team should review possible interactions and treatment-related risks.
Contact your oncology team for instructions if you miss a scheduled injection or appointment. Do not receive an extra dose or change the dosing schedule yourself.
Food does not directly affect Tecvayli because it is administered as an injection under the skin rather than taken orally. Follow your healthcare provider’s dietary recommendations.
Attend all scheduled appointments and monitoring visits. Report fever, signs of infection, confusion, difficulty speaking, breathing problems or other unusual symptoms immediately.
Store Tecvayli in a refrigerator at 2°C to 8°C in its original carton to protect it from light. Do not freeze or shake the medicine.
Pharma Five may assist with information and import facilitation for personal medical use, subject to applicable regulations and required documentation. A valid prescription and supporting documents may be required. Pharma Five assists in its procurement.